Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RP101
- Development stage
- Phase 2
- Lead developer
- RESprotect
- Modality
- Small Molecules, Hydrogel Systems → Drug Delivery Systems
- Administration
- Oral, Ophthalmic
01
Overview
RP101 refers to two distinct investigational drug candidates. The first is a first-in-class, orally administered small molecule inhibitor of Heat Shock Protein 27 (Hsp27), originally developed by RESprotect GmbH for the treatment of pancreatic and other gastrointestinal cancers. RedHill Biopharma previously held an option to acquire this candidate but terminated the agreement in 2017. The second is a topical ophthalmic formulation of 17-beta-estradiol developed by Redwood Pharma for the treatment of moderate-to-severe dry eye disease (DED) in postmenopausal women. This version utilizes the IntelliGel drug delivery system, a thermosensitive supramolecular hydrogel that permits sustained drug delivery on the ocular surface by gelling at eye temperature.
- Other names
- 17-beta-estradiol
02
Targets
HSPB1 (Heat shock protein beta-1)ER (Estrogen receptor)
Beyond the preview
Go deeper on RP101.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RP101.